Table 1. Risk of Cancers for Members of Families That Fulfilled Amsterdam I Criteria.
| Cancer Site | SMR (95% CI) | |||
|---|---|---|---|---|
| Proband | First-Degree | Second-Degree | First-Cousin | |
| Esophagus | 4.82 (0.122-26.88) | 1.91 (0.39-5.58) | 0.65 (0.08-2.33) | 0.74 (0.20-1.89) |
| Stomach | 2.33 (0.06-12.99) | 5.46 (3.24-8.64) | 3.50 (2.17-5.35) | 1.59 (0.96-2.49) |
| Small intestine | 8.14 (0.21-45.33) | 0.98 (0.03-5.43) | 1.87 (0.51-4.79) | 1.95 (0.78-4.02) |
| Colorectum | NAa | 15.60 (10.05-17.27) | 6.43 (5.69-7.23) | 1.86 (1.58-2.17) |
| Colon | NAa | 17.48 (15.49-19.65) | 6.73 (5.82-7.74) | 1.99 (1.65-2.39) |
| Rectum | NAa | 14.40 (11.72-17.52) | 6.65 (5.33-8.21) | 1.89 (1.39-2.51) |
| Liver | 0 | 0 | 0.89 (0.11-3.23) | 1.93 (0.78-3.97) |
| Pancreas | 1.56 (0.04-8.72) | 2.15 (1.08-3.85) | 1.90 (1.13-3.00) | 1.62 (1.09-2.31) |
| Lung | 2.43 (0.79-5.68) | 1.15 (0.68-1.82) | 1.26 (0.88-1.74) | 1.68 (1.36-2.06) |
| Breast | 0.79 (0.16-2.30) | 1.36 (0.99-1.81) | 1.32 (1.07-1.61) | 1.19 (1.00-1.39) |
| Melanoma | 2.05 (0.56-5.26) | 1.46 (0.93-2.17) | 1.31 (0.97-1.73) | 0.98 (0.74-1.29) |
| Endometrium | 6.14 (2.25-13.37) | 1.93 (1.12-3.09) | 1.60 (1.06-2.33) | 1.00 (0.69-1.42) |
| Ovary | 2.03 (0.05-11.31) | 0.46 (0.06-1.64) | 0.69 (0.25-1.49) | 1.32 (0.82-2.02) |
| Prostate | 1.47 (0.67-2.79) | 2.27 (1.85-2.76) | 1.90 (1.61-2.22) | 1.38 (1.20-1.58) |
| Kidney | 3.23 (0.39-11.65) | 3.21 (1.83-5.21) | 0.86 (0.39-1.64) | 1.61 (1.07-2.33) |
| Urinary bladder | 1.64 (0.20-5.91) | 1.88 (1.09-3.01) | 1.41 (0.89-2.12) | 1.35 (0.98-1.81) |
| Brain | 2.71 (0.07-15.08) | 4.13 (2.20-7.06) | 2.24 (1.30-3.58) | 1.16 (0.60-2.01) |
| Thyroid | 0 | 2.23 (1.02-4.23) | 1.98 (1.27-2.95) | 1.01 (0.52-1.77) |
| Non-Hodgkin lymphoma | 0 | 2.13 (1.30-3.30) | 1.33 (0.86-1.97) | 1.10 (0.77-1.52) |
| Myeloma | 0 | 1.89 (0.69-4.11) | 0.86 (0.28-2.00) | 1.22 (0.67-2.05) |
| Leukemia | 0 | 1.33 (0.61-2.53) | 1.58 (0.99-2.40) | 1.52 (1.07-2.11) |
Abbreviations: NA, not applicable; SMR, standardized morbidity ratio.
a
No risk estimates can be computed for cancer sites in probands that are part of central definition of Amsterdam I criteria.